Company news
BioRestorative Therapies, Inc. news in 2023
BioRestorative Therapies, Inc.'s news releases, calls and decks from 2023, newest first.
BioRestorative Therapies Receives a Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its Obesity Program
December 11, 2023
BioRestorative Therapies Enters into Supply Agreement with Evolutionary Biologics
September 11, 2023
BioRestorative Therapies Announces Activation of Northwell Health in the Company's Phase 2 Clinical Trial Targeting Chronic Lumbar Disc Disease
September 7, 2023
BioRestorative Therapies (NASDAQ: BRTX) Receives Landmark License From New York State
July 20, 2023
BioRestorative Therapies Announces $2.1 Million Registered Direct Offering
July 10, 2023
BioRestorative Therapies' Drug Candidate BRTX-100 Passes Safety Test With Flying Colors, Moves Ahead With Phase 2 And Looks To Expand Pipeline Opportunities
July 6, 2023
BioRestorative Therapies Receives Unanimous Recommendation from Data Safety Monitoring Board (DSMB) to Continue its Phase 2 Clinical Trial without any Changes
June 26, 2023
BioRestorative Therapies Announces Key Milestone of Dosing Completion in Safety Cohort of Phase 2 Trial Targeting Chronic Lumbar Disc Disease
June 11, 2023
BioRestorative Therapies Receives License from New York State Department of Health to act as Tissue Bank for Mesenchymal Stem Cell Processing
May 30, 2023
BioRestorative Therapies Receives Notice of Allowance by the Japanese Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
May 14, 2023
BioRestorative Therapies and Northwell Health Enter into Agreement to Participate in the Company’s Phase 2 Clinical Trial
May 7, 2023
BioRestorative Therapies Announces Completion of Patient Enrollment for Safety Run-In Component of its Phase 2 Clinical Study of BRTX-100
April 23, 2023
BioRestorative Therapies to Seek FDA Approval to Expand the Clinical Application of BRTX-100
March 12, 2023
BioRestorative Therapies Receives Notice of Allowance by the United States Patent and Trademark Office for a Patent Application Related to its ThermoStem® Program
March 1, 2023
BioRestorative Therapies Inc (NASDAQ: BRTX) Announces European Patentability Of ThermoStem® Program With Indications In Obesity And Type 2 Diabetes
February 9, 2023
BioRestorative Therapies Announces Notice of Allowance by the European Patent Office for Patent Related to its ThermoStem® Program
February 7, 2023
Decks in 2023
- Investor Presentation (August 2023)
Investor deck · 23 slides · August 2023
- Investor Presentation (April 2023)
Investor deck · 22 slides · April 2023
- Investor Presentation (January 2023)
Investor deck · 23 slides · January 2023